BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
(Reuters) — Shares in Germany's Bayer AG fell more than 12% on Wednesday after a second U.S. jury ruled its Roundup weed killer caused cancer.
Tuesday's unanimous jury decision in San Francisco federal court was not a finding of Bayer's liability for the cancer of plaintiff Edwin Hardeman. Liability and damages will be decided by the same jury in a second trial phase beginning on Wednesday.
Bayer, which denies allegations that glyphosate or Roundup cause cancer, said it was disappointed with the jury's initial decision. Bayer acquired the Monsanto Co., the longtime maker of Roundup, for $63 billion last year.
Bayer shares were 12.5% lower, the biggest intraday loss in 16 years, wiping some 8 billion euros ($9.1 billion) off its valuation.
"This looks like 2-0 plaintiffs, and clearly not helpful for the overall payout calculus and resolution of the litigation," said Bernstein analyst Gunther Zechmann.
Glyphosate is the world's most widely used weed killer. Monsanto's Roundup was the first glyphosate-based weed killer but is no longer patent-protected and many other versions are now available. Bayer does not provide sales figures for the product.
"We are confident the evidence in phase two will show that Monsanto's conduct has been appropriate and the company should not be liable for Mr. Hardeman's cancer," the company said.
The case was only the second of some 11,200 Roundup lawsuits to go to trial in the United States. Another California man was awarded $289 million in August after a state court jury found Roundup caused his cancer. That award was later reduced to $78 million and is on appeal.
Baader Helvea analyst Markus Mayer noted that Bayer management announced ambitious targets in December.
"(It) is now under pressure to deliver and trying to avoid becoming a target for activist or strategic buyers."
Activist investor Elliott Corp. already holds a stake of less than 3% in Bayer, Reuters disclosed last year.
Brokerage Warburg lowered its recommendation to "Hold" from "Buy," arguing that with the renewed setback, upcoming glyphosate court cases would remain a drag on the share price.
Bayer had claimed that jury was overly influenced by plaintiffs' lawyers allegations of corporate misconduct and did not focus on the science.
U.S. District Judge Vince Chhabria called such evidence "a distraction" from the scientific question of whether glyphosate causes cancer. He split the Mr. Hardeman case into two phases: one to decide causation, the other to determine Bayer's potential liability and damages.
Under Judge Chhabria's order, the second phase would only take place if the jury found Roundup to be a substantial factor in causing Mr. Hardeman's non-Hodgkin's lymphoma. The jury found that it was on Tuesday.
Union Investment fund manager Markus Manns cautioned that it was too early to read anything into individual rulings in courts of first instance.
"What will be important for Bayer is the outcome of the appeals hearings," he told Reuters, adding that Bayer should not yet engage in settlement talks.
Judge Chhabria has scheduled another bellwether trial for May and a third trial is likely to take place this year. All three cases will be split into causation and liability phases.
The U.S. Environmental Protection Agency, the European Chemicals Agency and other regulators have found that glyphosate is not likely carcinogenic to humans. But the World Health Organization's cancer arm in 2015 reached a different conclusion, classifying glyphosate as "probably carcinogenic to humans."
(Reuters) — Bayer AG’s chief executive said this week the company might consider settling lawsuits over Monsanto’s glyphosate-containing weedkillers depending on how high court costs rise, but stressed it remained focused on defending the combined company against claims they cause cancer.